New integrated MES/HMI solution.

At this year’s PAS-X User Group Meeting in Parsippany, (NJ USA), Werum IT Solutions and Systec & Solutions presented a new, jointly developed approach for enhanced usability in controlling pharmaceutical and biopharmaceutical production processes on the shop floor.

Rüdiger Schlierenkämper, Werum 

& Andreas König, Systec & Solutions

Customers who want to introduce Werum‘s PAS-X MES solution will now also have access to a range of specifically tailored Systec & Solutions HMI hardware. “Such compatible components allow for a more reliable and accelerated MES introduction, giving customers a clear advantage over third-party components that require various adjustments and tests to work together optimally,” says Rüdiger Schlierenkämper, CEO, Werum IT Solutions GmbH. “Our objective is to simplify the automation of production processes for our pharma customers while providing them with standard solutions for ergonomic and safe operation by design.”

“Another advantage for Werum and Systec & Solutions customers,” adds Andreas König, Managing Director at Systec & Solutions GmbH, “is that the Systec & Solutions HMI hardware has pre-configured components with additional functions such as hardware buttons to switch between different PAS-X applications. This will help make the work of shop floor operators more reliable, as well as faster and easier. ” The mobile stainless steel trolleys of Systec & Solutions are battery-powered so that the HMI can be used together with the PAS-X MES software wherever required by the process.

The development of effective joint solutions is based on the long-term pharma and biotech experience of both Werum and Systec & Solutions. “Customers who want to use the Systec & Solutions hardware while also operating the PAS-X MES can be assured of a fine-tuned and perfectly compatible solution,” says Schlierenkämper, while König adds, “By combining the innovative power of two premium suppliers, we are well positioned to boost forward-looking improvements for our customers, and look forward to continuing our work together to develop new ideas for pharmaceutical and biopharmaceutical production.”